Basf Aktiengesellschaft

Abbott Laboratories Corporation

Abbvie Inc.

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Abb Vie Deutschland Gmbh & Co. Kg

Barrier Therapeutics, Inc.

Gunther Berndl

Bernd Liepold

Axel Sanner

Laman L Alani

Soumojeet Ghosh

Ulrich Reinhold

Joerg Rosenberg

Joerg Breitenbach

Helmut Meffert

Stephan Kothrade

J&ouml;rg Breitenbach

Jörg Breitenbach

Folker Ruchatz

Matthias Degenhardt

Jörg Rosenberg

Jorg Breitenbach

Karl Kolter

Kurt H Bauer

Dirk Simon

Thomas Kessler

J&ouml;rg Rosenberg

Andreas Ernst

J&uuml;rgen Zeidler

Gerrit Dispersyn

Katja Fastnacht

Jorg Rosenberg

Volker Schehlmann

Stefan Stein

Heinrich Sack

Knut Kessel

Robert Heger

Christoph Schmidt

Andreas Kleinke

G&uuml;nter Scherr

Thomas Bogenst&auml;tter

John B Morris

Ulrich Westedt

Ute Lander

Markus Mägerlein

Harald Krull

J&ouml;rg Neumann

Markus Maegerlein

Peter Wilke

Christiane Vollgraf

Bernd Leipold

Juergen Weis

Michael Stadler

Jeorg Rosenberg

Markus Mäegerlein

Jöerg Rosenberg

Dietrich Granzow

Cheri E Klein

Joeerg Rosenberg

Yan Cai

Wolfgang Roth

Tina Jung

Jorg Neumann

A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Solid retard formulations based on solid dispersions

A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (), each of the shafts () carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element () which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.

Process for producing a solid dispersion of an active ingredient

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein &#x394;Hrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C.). The solid dispersion product shows an improved bioavailability.

Itraconazole compositions with improved bioavailability

A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein AHrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.

Dosage forms with improved bioavailability

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50&#xb0; C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Solid pharmaceutical dosage form

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein &#x394;Hrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C). The solid dispersion product shows an improved bioavailability.

The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.

Self-emulsifying active substance formulation and use of this formulation

The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Solid pharmaceutical dosage formulation

The invention relates to excipients in powder form for use in solid pharmaceutical presentations, comprising a pharmaceutically acceptable polymer and a liquid or semisolid solubilizing surface-active substance.

Solubilizing aids in powder form for solid pharmaceutical presentation forms

The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing agents, c) 0.1 to 49.5 wt. % of at least one active principle, at a temperature not less than the softening temperature of the adjuvant but rising to at least 70&#xb0; C.; then in cooling the resulting paste. Said solid galenic formulations quickly disintegrate in an aqueous medium.

Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier

Growing community of inventors

Herxheim, Germany

Gunther Berndl